The National Institutes of Health is proposing to help enhance public access to drugs, biologics, vaccines and medical device products stemming from taxpayer-funded inventions by requiring that patent licensing arrangements made through its Intramural Research Program include a plan to achieve that goal.
Key Takeaways
-
NIH Intramural Research Program's proposed new licensing policy for drugs, biologics, vaccines and devices would require partners to develop a plan to promote public access to products stemming from taxpayer-funded inventions.
The plan could, but would not be required to, include ways to ensure affordability through pricing commitments, according to the...






